The world of cancer treatment is ever-evolving, and staying up-to-date is crucial for healthcare professionals. But here's where it gets technical: understanding the nuances between genetic and genomic studies is essential for oncology navigators. At the recent AONN+ Conference, Jennifer Aversano shed light on this very topic, focusing on genomic testing for non-small cell lung cancer (NSCLC).
Genetics vs. Genomics: Unlocking the Code
Aversano began by demystifying the difference between genetics and genomics. Genetics, she explained, is the study of family history and how certain conditions are inherited, which is crucial for germline testing in specific cancers like breast and ovarian.
But genomics takes a different approach, focusing on the unique genetic makeup of a cancerous tumor. It involves somatic testing to identify mutations that are not inherited. This is particularly relevant for lung cancer, among others.
Lung Cancer Statistics: A Sobering Reality Check
Aversano didn't shy away from the harsh facts. She shared that lung cancer will affect approximately 2 million people in the US this year, making it the leading cause of cancer death. A staggering statistic that emphasizes the need for advanced testing and treatment options.
Molecular Testing in NSCLC: A Stage-by-Stage Guide
The presentation delved into the specifics of molecular testing for NSCLC, offering recommendations for each stage. For instance, in stages IB to IIIA and IIIB (T3-4, N2), tumors over 4 cm or node-positive should be considered for neoadjuvant therapy, with tests for PD-L1, EGFR mutations, and ALK arrangements.
And this is the part most people miss: for advanced or metastatic NSCLC, the recommendation is broad panel-based next-generation sequencing (NGS) and PD-L1 testing to identify emerging biomarkers.
Aversano also referenced the NCCN guidelines for molecular and biomarker-directed therapy in advanced NSCLC, providing a comprehensive roadmap for patient care.
Case Studies: Personalizing Treatment
To bring the theory to life, Aversano presented case studies showcasing the various types of NSCLC and the treatment paths available based on stage, history, and molecular testing. This personalized approach highlights the importance of molecular testing in improving survival rates for lung cancer patients.
In conclusion, Aversano stressed that while lung cancer remains the deadliest, the survival rate is rising, and molecular testing plays a pivotal role in this progress. But is this enough? Are we doing all we can to combat this devastating disease? Share your thoughts in the comments below.
